Diabetes Clinical Trials in Houston
View 164 new treatments for Diabetes in Houston, TX, and nearby areas, such as League City, Pearland and Sugar Land. Every day, Power helps hundreds of diabetes patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
Umbilical Cord Patch (TTAX01) for Diabetic Foot Ulcers
Tissue Tech Clinic, Houston + 3 more
It is hypothesized that application at 4-week or greater intervals of the human placental umbilical cord tissue TTAX01 to the surface of a well debrided, complex diabetic foot ulcer (DFU) will, with concomitant management of infection, result in a higher rate of wounds showing complete healing within 25 weeks of initiating therapy, compared with standard care alone. This second confirmatory Phase 3 study examines a population of diabetic foot ulcer patients having adequate perfusion, with or without neuropathy, and a high suspicion of associated osteomyelitis in a complex, high grade wound.Show More
Verified
Recruiting
No Placebo Trial
Phase 3
Est. 3 - 6 Weeks
Herbert Slade, MD
Study Chair
INV 202 for Diabetic Kidney Disease
Inversago Clinic, Pearland + 5 more
This trial tests a new drug called INV-202 in adults with Diabetic Kidney Disease caused by Type 1 or Type 2 diabetes. The goal is to see if the drug is effective, safe, and well-tolerated, and how it behaves in the body.Show More
Verified
Recruiting
Phase 2
Est. 5 - 8 Weeks
Glenn Crater, MD
Study Director
PF-07081532 + Rybelsus for Type 2 Diabetes and PF-07081532 for Obesity
Pfizer Clinic, Katy + 4 more
This trial is testing a new drug called PF-07081532 to see if it can help people lose weight or control their blood sugar. The study includes obese individuals without diabetes and diabetic patients already taking metformin. Participants will receive either the new drug or an approved treatment and will be monitored over time.Show More
Verified
Recruiting
Phase 2
Est. 6 - 12 Weeks
Pfizer CT.gov Call Center
Study Director
RESET Liner for Type-2 Diabetes and Obesity
Morphic Clinic, Houston + 1 more
This trial is testing the RESET System, a device placed in the stomach, to help people with Type 2 Diabetes and Obesity who haven't controlled their blood sugar well with current medications. The device works by reducing food absorption, aiding in better blood sugar control and weight loss. The RESET System has been shown to help with weight loss and better blood sugar control in patients with type 2 diabetes.Show More
Verified
Recruiting
N/A
Est. 6 - 12 Weeks
Christopher C Thompson, MD
Principal Investigator
ILUVIEN® Implant for Diabetic Macular Edema
Alimera Sciences Clinic, Houston + 2 more
This is a randomized, masked, active-controlled, parallel-group, multi-center study that will assess the efficacy of ILUVIEN as a baseline therapy in the treatment of Center Involving DME (CI-DME). The study will enroll patients who are either treatment naïve or have not received any DME treatments for the preceding 12 months as documented in medical records. Patients who received DME treatment \>12 months before screening, must not have received \>4 intravitreal injections. The study will compare 2 treatment regimens: ILUVIEN intravitreal implant (0.19 mg) followed by supplemental aflibercept as needed per protocol criteria (2 mg/0.05 mL), compared to intravitreal aflibercept loading dose (2 mg administered by intravitreal injection every 4 weeks for 5 consecutive doses) followed by supplemental aflibercept as needed per protocol criteria (2 mg/0.05 mL).Show More
Waitlist
No Placebo Trial
Phase 4
Est. 3 - 12 Weeks
Samer Kaba, MD
Study Chair
Metformin for Prediabetes
Research Clinic, Houston + 1 more
This trial is testing whether metformin can lower the risk of death, heart attacks, and strokes in people with pre-diabetes and heart or blood vessel issues. Metformin is a drug that helps control blood sugar levels and has been used to treat type 2 diabetes mellitus for more than 60 years. The study involves patients who have pre-diabetes and existing heart or blood vessel problems, aiming to see if metformin can provide additional health benefits.Show More
Recruiting
Phase 4
Est. 4 - 6 Weeks
Gregory G. Schwartz, PhD MD
Study Chair
Faricimab for Diabetic Macular Edema
Research Clinic, Bellaire + 2 more
This study will assess a pragmatic, treat and extend regimen of faricimab against the standard of a fixed dosing regimen.
Recruiting
No Placebo Trial
Phase 4
Est. 3 - 12 Weeks
Dr. Varun Chaudhary, MD, FRCS(C)
Principal Investigator
A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)
Eli Lilly Clinic, Houston + 1 more
This trial is testing a new medication called tirzepatide for people with type 2 diabetes. Tirzepatide helps control blood sugar by making the body produce more insulin and reducing appetite. The study aims to see if switching to this new treatment is more effective than current therapies.Show More
Waitlist
No Placebo Trial
Phase 4
Est. 6 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
GLP-1 Therapy for Diabetes
Research Clinic, Houston + 1 more
This project investigates the anti-obesity mechanisms of glucagon-like peptide-1 (GLP-1) analogs, which are used in the treatment of human obesity and diabetes mellitus. The investigators will test if GLP-1 induces secretion of interleukin-6 (IL-6), a cytokine that may collaborate with GLP-1 analogs to induce the formation of brown fat, which has anti-diabetic properties. The results will guide future obesity and diabetes mellitus therapies.Show More
Waitlist
Phase 4
Est. 5 - 8 Weeks
Absalon D Gutierrez, MD
Principal Investigator
Risankizumab for Inflammatory Bowel Disease
AbbVie Clinic, Houston + 1 more
Inflammatory bowel disease (IBD) is a chronic inflammatory disease that requires lifelong treatment. This study will asses the concentrations of risankizumab in the breast milk of lactating women with IBD Risankizumab is an approved drug for adults with plaque psoriasis, psoriatic arthritis, and Crohn's Disease. This is an open-label milk-only study lactation study to evaluate the presence of risankizumab in the milk of lactating women. Approximately 10 adult lactating women with IBD will be enrolled from approximately 3 sites in Israel and or the United States. Participants will receive risakizumab maintenance therapy every 8 weeks postpartum prior to start of participation in this study. The study duration is approximately 7 months. Participants will attend regular visits during the study at a hospital or clinic. The participants will also be completing questionnaires and will have medical assessments, checking for side effects.Show More
Recruiting
No Placebo Trial
Phase 4
Est. 3 - 12 Weeks
ABBVIE INC.
Study Director
Page 1 of 12
Frequently Asked Questions
Explore related conditions